KIDS OrthoPediatrics Corp

OrthoPediatrics Corp. to Present at Four Upcoming Investor Conferences in November and December

OrthoPediatrics Corp. to Present at Four Upcoming Investor Conferences in November and December

WARSAW, Ind., Oct. 29, 2020 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq:KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced that Mark Throdahl, Chief Executive Officer, Fred Hite, Chief Operating Officer and Chief Financial Officer, and Dave Bailey, President, are scheduled to participate at three upcoming virtual investor conferences in November.

Event:Credit Suisse 29th Annual Virtual Healthcare Conference
Format:Presentation and One-on-One Meetings
Date:Wednesday, November 11, 2020
Time:1:15pm ET
  
Event: Stifel 2020 Virtual Healthcare Conference
Format:Fireside Chat and One-on-One Meetings
Date: Wednesday, November 18, 2020
Time: 10:40am ET
  
Event:Canaccord Genuity 2020 Virtual MedTech & Diagnostics Forum
Format:Presentation and One-on-One Meetings
Date: Thursday, November 19, 2020
Time: 3:00pm ET
  
Event: Piper Sandler 32nd Annual Virtual Healthcare Conference
Format:Fireside Chat and One-on-One Meetings
Date: Tuesday, December 1, 2020 (meetings)

An audio webcast of the Stifel presentation will be available online at OrthoPediatrics’ investor relations website, . Additionally, a replay will be available for 90 days after the presentation.

Investors attending the conference who would like to schedule a one-on-one meeting with OrthoPediatrics management may do so by contacting their Credit Suisse, Stifel, Canaccord Genuity, or Piper Sandler representative, or Jan Medina of The Ruth Group at .

About OrthoPediatrics Corp.

Founded in 2006, OrthoPediatrics is an orthopedic company focused exclusively on advancing the field of pediatric orthopedics. As such it has developed the most comprehensive product offering to the pediatric orthopedic market to improve the lives of children with orthopedic conditions. OrthoPediatrics currently markets 35 surgical systems that serve three of the largest categories within the pediatric orthopedic market. This product offering spans trauma and deformity, scoliosis, and sports medicine/other procedures. OrthoPediatrics’ global sales organization is focused exclusively on pediatric orthopedics and distributes its products in the United States and 43 countries outside the United States. For more information, please visit .

Investor Contacts

The Ruth Group

Jan Medina, CFA

(646) 536-7035

EN
29/10/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on OrthoPediatrics Corp

 PRESS RELEASE

OrthoPediatrics to Participate in Upcoming Conferences

OrthoPediatrics to Participate in Upcoming Conferences WARSAW, Ind., Nov. 04, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, a company focused exclusively on advancing the field of pediatric orthopedics, today announced that it will participate in three upcoming investor conferences. Event: Stifel 2025 Healthcare Conference Format: Fireside Chat Date: Thursday, November 13, 2025Time: 1:20 pm ET Event: Jeffries Global Healthcare Conference in LondonFormat: P...

 PRESS RELEASE

OrthoPediatrics Corp. Reports Third Quarter 2025 Financial Results

OrthoPediatrics Corp. Reports Third Quarter 2025 Financial Results Increased Third Quarter 2025 Revenue 12% Year-over-year, and Increased Adjusted EBITDA by 56% year-over-year WARSAW, Ind., Oct. 28, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced its financial results for the third quarter ended September 30, 2025. Third Quarter 2025 and Recent Business Highlights       Helped over 37,000 children in the third quarter of 2025 and approximat...

 PRESS RELEASE

OrthoPediatrics Corp. Receives FDA approval for 3P™ Pediatric Plating ...

OrthoPediatrics Corp. Receives FDA approval for 3P™ Pediatric Plating Platform™ Small-Mini System, the second of several systems in the 3P family WARSAW, Ind., Oct. 28, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced the FDA approval of its 3P™ Pediatric Plating Platform™ Small-Mini System, the second of several systems in the 3P family. This represents the company’s 6th FDA approval in 2025. The 3P Small-Mini System is a versatile plate and s...

 PRESS RELEASE

OrthoPediatrics Corp. to Report Third Quarter Financial Results on Oct...

OrthoPediatrics Corp. to Report Third Quarter Financial Results on October 28, 2025 WARSAW, Ind., Oct. 15, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced that the Company is scheduled to release its third quarter 2025 financial results on October 28, 2025 after the market closes. OrthoPediatrics will host a conference call on Tuesday, October 28, 2025 at 4:30 p.m. ET to discuss the results. Investors interested in listening to the conference ...

 PRESS RELEASE

OrthoPediatrics Corp. Announces Preliminary Third Quarter 2025 Revenue...

OrthoPediatrics Corp. Announces Preliminary Third Quarter 2025 Revenue and Revised 2025 Guidance Company to host conference call today, October 9th, 2025, to discuss the financial results and updated outlook WARSAW, Ind., Oct. 09, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced preliminary unaudited financial highlights for the third quarter ended September 30, 2025, and revised 2025 financial guidance. Preliminary Third Quarter 2025 Results...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch